Ovid Therapeutics Inc. (OVID) Reports In-Line Q1 EPS

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $79.6 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• KeyCorp (KEY) files for 158.72M share offering by selling stockholders
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits